The pharmaceutical company Vita announced that it has raised $ 32 million to advance its work in cell therapy for muscular dystrophic diseases.
This budget will support further clinical trials of VTA-100, a major candidate for the treatment of 2A / R1 limb girdle muscular dystrophy, the most common form of limb girdle disease. The company is planning to apply to the US Food and Drug Administration (FDA) for VTA-100 clinical trials.